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ABSTRACT
Objective: The objective of the current work was to synthesize a series of 3,4-substituted pyrazoles from the cyclization of substituted aryl ethanone 
and hydrazine hydrate in a two-step process and screen the derivatives for their antimicrobial activity.
Methods: The title compounds were derived from the condensation of ethanone intermediate with N, N-Dimethyl formamide-dimethyl acetal and 
hydrazine hydrate. Ethanone intermediate synthesized from substituted methyl phenylacetate in the presence of potassium t-butoxide with 6-methyl 
pyridine-2-carboxylic acid methyl ester.
Results: The final products were characterized by detailed spectral analysis using Mass, Nuclear Magnetic Resonance, and Infra Red spectroscopy. 
All the compounds (4a-4j) showed significant antibacterial properties on both Gram-positive and Gram-negative bacteria. Interestingly, the selected 
microbes were found to be highly sensitive for compound 4a, 4c, 4d, 4h, and 4i. The molecules are also antifungal in nature, and they have a significant 
inhibitory effect on the growth of Candida albicans and Aspergillus niger.
Conclusion: The results suggest that the developed derivatives bearing the pyrazole nucleus could be the lead structures for the development of 
antimicrobial agents for fatal infections.
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INTRODUCTION
Various substituted pyrazole based drugs are acquiring significance in 
medicinal and natural products research by virtue of its multifarious 
properties and broad spectrum of applications for various 
ailments [1]. Specifically, substituted pyrazoles create a critical position 
in the pharmaceutical industry as they comprise the important 
structure for many commercial drugs such as sildenafil, celecoxib, and 
rimonabant.
The abundant texts support the ubiquitous nature of aza-heterocyclic 
compounds, the pyrazole derivatives. They are documented 
to possess anticancer [2-4], antibacterial [5], antifungal [6,7], 
antitubercular [8,9], analgesic [10,11], antimalarial [12,13], 
antipyretic [14], anticonvulsant [15], antidepressant [16], 
antiangiogenetic [17], antidiabetic [18], antiviral [19,20], and anti-
inflammatory [21-23] activities.
Since the foundation of the primary synthetic method of pyrazole, 
i.e., Paal–Knorr synthesis by condensation of 1,3-diketones with 
hydrazine which yields substituted pyrazoles, it is the subject matter 
for investigators to create the substituted pyrazoles. Due to the 
convenience and versatility, Paal–Knorr synthesis had been the principal 
synthetic method for pyrazole synthesis. There are many customary 
methodologies for the synthesis of various pyrazole derivatives. A lot 
of literature in correlation to the variation of Paal–Knorr synthesis with 
better yields, reported by researchers, by usurping one of the starting 
material 1,3-diketone with acetylenic and olefinic ketone moieties. 
Individual substances have been cultivated for producing distinct 
pyrazole crossbreeds. To overwhelm the severe reaction conditions and 
to have regioselectivity, a basic and beneficial strategy was utilized for 
the synthesis of substituted pyrazoles.
EXPERIMENTAL
Methods
For the current work, synthetic grade chemicals were utilized and 
purchased from Sigma-Aldrich. Merck-pre-coated aluminum thin-
layer chromatography plates of silica gel 60 F254 of 0.5 thickness 
were employed and spots were observed under ultraviolet light. Pure 
compounds were isolated from the crude mixture by the column 
chromatography and the pure compounds were recrystallized with 
ethanol. Remi electronic melting point apparatus was employed for 
the melting points determination. Infrared (IR) spectra were recorded 
on Agilent Fourier-transform IR by KBr pellet method. Proton nuclear 
magnetic resonance (1H NMR) recorded on VARIAN – 400 MHz. The 
splitting patterns are designated as follows: s, singlet; d, doublet; t, 
triplet; q, quartet; and m, multiplet. MASS recorded on BRUKER ESI-IT MS. 
The bacterial and fungal strains were obtained from the Department 
of Microbiology, Osmania University, Hyderabad. The samples were 
subcultured and preserved at 4°C.
General procedure for the synthesis of pyrazole derivatives [24]
Synthesis of ethanone intermediate
A solution of substituted methyl phenylacetate (15 mmol) potassium 
t-butoxide (45 mmol) and 6-methyl pyridine-2-carboxylic acid methyl 
ester (15 mmol) in tetrahydrofuran (75 mL) was heated at 65°C for 48 h. 
The mixture was concentrated under vacuum and treated carefully with 
concentrated hydrochloric acid (10 mL). The resulting mixture was 
heated at 100°C for 12 h. The mixture was cooled to room temperature 
and the pH adjusted to 9.0 with 6 N sodium hydroxide solution. The 
mixture was extracted with ethyl acetate, and the organic layer dried 
and concentrated under vacuum. The final product was purified by 
column chromatography with hexane/ethyl acetate mobile phase.
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Synthesis of pyrazole derivatives
A solution of ethanone intermediate (5 mmol) in tetrahydrofuran 
(20 mL) was treated with N, N-Dimethyl formamide-dimethyl acetal 
(50 mmol) and stirred for 40 h. The mixture was concentrated under 
vacuum, diluted with ethanol (10 mL), and treated with hydrazine 
monohydrate (150 mmol). The resulting mixture was stirred for 8 h, 
concentrated, diluted with ethyl acetate, and washed once with water. 
The combined organic layers concentrated in vacuum and crude 
product of pyrazole was purified by column chromatography with the 
mobile phase hexane/ethyl acetate. The complete scheme of synthesis 
for the title compounds is depicted in Fig. 1.
Antimicrobial screening [25]
Antibacterial activity
Agar disk diffusion method with standard protocols was employed 
to screen the antibacterial activity of the titled compounds (4a-4j) at 
a dose of 100 µg/mL by agar plate method using standard protocols. 
For the antibacterial screening, two Gram-positive (Staphylococcus 
aureus and Bacillus subtilis) and two Gram-negative bacterial strains 
(Escherichia coli and Pipanacoctomys aureus) were selected. Standard 
neomycin sulfate and dimethyl sulfoxide (DMSO) were served as 
positive and negative control, respectively. The experiment was done in 
triplicates and the zone of inhibition measured in mm was taken for the 
evaluation of the antibacterial activity of the test compounds.
Peptone, meat extract, and sodium chloride were dissolved in distilled 
water, and pH of the medium was adjusted to 7.2. Agar was dissolved and 
distributed in 40 mL quantities into 100 mL flasks and was sterilized 
in an autoclave at 121°C (15 lbs/sq.in) for 20 min. The medium was 
inoculated at 1% level with 18 h of old cultures of the above-mentioned 
test organism and transferred into sterile 15 cm diameter Petri dishes. 
The medium in the plates could set at room temperature for 30 min. 
For the preparation of cup agar plates, 6 mm diameter holes were 
made with the help of a sterile borer at the corner of the plate at equal 
distance. The solution of test compounds was placed in the cups by 
means of sterile pipettes. In each plate, one cup was used for control 
with two drops (0.05 mL) of DMSO neomycin sulfate in 10 µg/mL, 
concentration was used as standard. The plates could incubate at room 
temperature for 1 h to diffuse. Then, the plates were incubated for 24 h 
at 37°C and zone of inhibition was recorded. The experiments were run 
in duplicate and the average diameter of the zones of inhibition was 
recorded and noted.
Antifungal activity
Two fungal strains, Candida albicans and Aspergillus niger were 
employed to test the antifungal activity of the title compounds in the 
concentration of 100 µg/mL using the above protocols. The experiments 
were done in triplicates on A. niger and C. albicans. Standard Nystatin 
and DMSO were served as positive and negative control, respectively. 
The zone of inhibition measured in millimeter was taken for the 
evaluation of an antifungal activity.
Dextrose and agar were added slowly to the filtered solution of peeled 
potatoes, which were pre-boiled in 200 mL of water for 30 min. Nystatin 
in 10 µg/mL concentration and DMSO was taken as standard and control, 
respectively. The diameter of the zones of inhibition was recorded after 
the incubation of plates at room temperature (30°C) for 48 h.
RESULTS AND DISCUSSION
Synthesis
Synthesized compounds structure and physicochemical data are 
depicted in Table 1.
Fig. 1: Scheme of synthesis for substituted pyrazoles
131
Asian J Pharm Clin Res, Vol 13, Issue 1, 2020, 129-133
 Akula et al. 


















1H NMR: δ 7.23 (1H, ddd, J = 7.5, 4.8, 1.5 Hz), 7.37–7.54 (3H, 7.49 
(dddd, J = 7.8, 7.5, 1.9, 0.4 Hz), 7.42 (tdd, J = 7.5, 1.7, 1.4 Hz), 
7.81 (2H, dddd, J = 7.8, 2.8, 1.7, 0.5 Hz), 7.86–7.99 2H, 7.96 (ddd, J = 8.1, 
1.5, 0.5 Hz), 7.91 (ddd, J = 8.1, 7.5, 1.8 Hz), 8.58 (1H, s), 8.70 (1H, ddd, 
J = 4.8, 1.8, 0.5 Hz). ESI-MS (m/z): [M+H]+ for C14H11N3is 222.6.
Compound 4b: 2-(4-(4-fluorophenyl)-1H-pyrazol-3-yl)pyridine
1H NMR: δ 2.19 (3H, s), 7.21–7.34 (3H, 7.30 (ddd, J = 7.5, 4.7, 1.3 Hz), 
7.24 (ddd, J = 8.2, 1.3, 0.5 Hz)), 7.81 (2H, ddd, J = 8.2, 1.7, 0.4 Hz), 
7.83–7.95 (2H, 7.92 (ddd, J = 7.9, 1.3, 0.5 Hz), 7.88 (ddd, J = 7.9, 7.5, 
1.8 Hz)), 8.51 (1H, s), 8.66 (1H, ddd, J = 4.7, 1.8, 0.5 Hz). ESI-MS (m/z): 
[M+H]+ for C14H10FN3is 240.15.
Compound 4c: 2-methyl-6-(4-phenyl-1H-pyrazol-3-yl)pyridine
1H NMR: δ 2.49 (3H, s), 7.31 (1H, dd, J = 7.8, 1.8 Hz), 7.39–7.52 (3H, 
7.47 (dddd, J = 7.8, 7.5, 1.5, 0.4 Hz), 7.44 (dddd, J = 7.5, 7.2, 1.4, 1.0 Hz), 
7.81–7.88 (3H, 7.85 (dd, J = 8.0, 1.8 Hz), 7.84 (dddd, J = 7.8, 2.6, 1.0, 
0.5 Hz)), 7.94 (1H, dd, J = 8.0, 7.8 Hz), 8.54 (1H, s). ESI-MS (m/z): [M+H]+ 
for C15H13N3is 236.08.
Compound 4d: 2-(4-(4-fluorophenyl)-1H-pyrazol-3-yl)-6-methylpyridine
1H NMR: δ 2.38 (3H, s), 7.11 (1H, dd, J = 7.8, 1.5 Hz), 7.21 (2H, ddd, 
J = 8.9, 1.5, 0.5 Hz), 7.41 (2H, ddd, J = 8.9, 1.4, 0.5 Hz), 7.84 (1H, dd, J = 7.9, 
1.5 Hz), 7.98 (1H, dd, J = 7.9, 7.8 Hz), 8.45 (1H, s).ESI-MS (m/z): [M+H]+ 
for C15H12FN3is 254.25.
Compound 4e: 2-(4-(4-chlorophenyl)-1H-pyrazol-3-yl)-6-methylpyridine
1H NMR: δ 2.40 (3H, s), 7.11 (1H, dd, J = 7.8, 1.5 Hz), 7.23 (2H, ddd, 
J = 8.8, 1.7, 0.5 Hz), 7.44 (2H, ddd, J = 8.8, 1.4, 0.5 Hz), 7.84 (1H, dd, 
J = 8.0, 1.5 Hz), 7.97 (1H, dd, J = 8.0, 7.8 Hz), 8.48 (1H, s). ESI-MS (m/z): 
[M+H]+ for C15H12ClN3is 270.6.
132
Asian J Pharm Clin Res, Vol 13, Issue 1, 2020, 129-133
 Akula et al. 
Compound 4f: 4-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)phenol
1H NMR: δ 2.34 (3H, s), 7.09 (1H, dd, J = 7.8, 1.8 Hz), 7.18 (2H, 
ddd, J = 8.9, 1.5, 0.5 Hz), 7.75 (2H, ddd, J = 8.9, 1.8, 0.5 Hz), 7.82 (1H, dd, 
J = 7.9, 1.8 Hz), 7.97 (1H, dd, J = 7.9, 7.8 Hz), 8.35 (1H, s). ESI-MS (m/z): 
[M+H]+ for C15H13N3Ois 252.3.
Compound 4g: 2-(4-(3,4-difluorophenyl)-1H-pyrazol-3-yl)-6-methylpyridine
1H NMR: δ 2.35 (3H, s), 7.09 (1H, dd, J = 7.8, 1.8 Hz), 7.18 (1H, dd, 
J = 8.8, 1.8 Hz), 7.51 (1H, dd, J = 8.8, 0.5 Hz), 7.61 (1H, dd, J = 1.8, 0.5 Hz), 
7.83 (1H, dd, J = 7.9, 1.8 Hz), 7.97 (1H, dd, J = 7.9, 7.8 Hz), 8.45 (1H, s). 
ESI-MS (m/z): [M+H]+ for C15H11F2N3is 272.1.
Compound 4h: 2-(4-(4-methoxyphenyl)-1H-pyrazol-3-yl)-6-methylpyridine
1H NMR: δ 2.32 (3H, s), 3.72 (3H, s), 7.07 (1H, dd, J = 7.8, 1.8 Hz), 
7.15 (2H, ddd, J = 8.9, 1.5, 0.5 Hz), 7.64 (2H, ddd, J = 8.9, 1.7, 0.5 Hz), 
7.81 (1H, dd, J = 7.9, 1.8 Hz), 7.96 (1H, dd, J = 7.9, 7.8 Hz), 8.37 (1H, s). 
ESI-MS (m/z): [M+H]+ for C16H15N3Ois 266.3.
Compound 4i: 2-(4-(3,4-dimethoxyphenyl)-1H-pyrazol-3-yl)-6-methylpyridine
1H NMR: δ 2.30 (3H, s), 3.69 (3H, s), 3.73 (3H, s), 6.88 (1H, dd, J = 8.8, 
0.4 Hz), 7.02 (1H, dd, J = 7.8, 1.7 Hz), 7.23 (1H, dd, J = 1.9, 0.4 Hz), 
7.29 (1H, dd, J = 8.8, 1.9 Hz), 7.93 (1H, dd, J = 7.8, 7.7 Hz), 8.02 (1H, dd, 
J = 7.7, 1.7 Hz), 8.28 (1H, s). ESI-MS (m/z): [M+H]+ for C16H15N3is 250.2.
Compound 4j: 2-methyl-6-(4-(p-tolyl)-1H-pyrazol-3-yl) pyridine
1H NMR: δ 2.18 (3H, s), 2.40 (3H, s), 7.07 (1H, dd, J = 7.8, 1.2 Hz), 
7.19 (2H, ddd, J = 8.2, 1.3, 0.5 Hz), 7.76–7.84 (3H, 7.82 (dd, J = 7.9, 
1.2 Hz), 7.79 (ddd, J = 8.2, 1.6, 0.5 Hz)), 7.96 (1H, dd, J = 7.9, 7.8 Hz), 
8.46 (1H, s). ESI-MS (m/z): [M+H]+ for C17H17N3O2 is 296.4.
Antibacterial activity
The antibacterial screening of the compounds (4a-4j) was screened 
against two Gram-positive, namely, S. aureus and B. subtilis, two 
Gram-negative, namely, Pseudomonas aeruginosa and E. coli using agar 
plate method. All the synthesized compounds display considerable 
antibacterial properties. Interestingly, compounds 4a, 4c, 4d, 4h, and 4i 
are showing comparatively higher inhibition to both Gram-positive and 
Gram-negative bacteria. The results are tabulated in Table 2.
The results of antifungal screening performed against C. albicans and 
A. niger are depicted in Table 3. Results display the antimicrobial 
potential of the title compounds against selected bacterial and fungal 
strains. The phenyl ring substituted with both electron-donating and 
electron-withdrawing groups produced considerable antimicrobial 
activity. From the above results, the substituted derivatives of pyrazoles 
are antimicrobial in nature. Remarkably, the compounds 4a, 4c, 4d, 4h, 
and 4i displayed good antimicrobial potential. The above findings can 
clear that these pyrazole derivatives can serve as lead molecules to the 
development of potent antimicrobial agents.
CONCLUSION
Various substituted pyrazole derivatives have been synthesized in a 
two-step process involving the cyclization of ethenone intermediate 
with hydrazine moiety. The simple procedure under reflux conditions 
leads to the synthesis 10 derivatives (4a-4j). The structures were 
established by detailed spectral analysis. Antimicrobial studies were 
performed on the synthesized compounds against selected microbial 
strains and the results revealed the antibacterial, antifungal properties. 
From the results, it can be concluded that further investigation is needed 
to understand the exact mechanism of the antimicrobial property in 
molecular level to develop potent antimicrobial agents to eradicate the 
pathogenic diseases caused by the bacteria and fungi.
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